Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsHAM:HTD +0.87%85 EV-to-FCF is 111.69 as of Aug. 12, 2026, which is 479% above its 10-year median of 19.29. GuruFocus rates HAM:HTD with a GF Score™ of 85/100 and a GF Value™ of €59.87 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 332 Biotechnology companies, Corcept Therapeutics ranks worse than 89.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Corcept Therapeutics's Enterprise Value is €10,214.1 Mil.
Corcept Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €91.4 Mil. Therefore, Corcept Therapeutics's EV-to-FCF for today is 111.69.
The historical rank and industry rank for Corcept Therapeutics's EV-to-FCF or its related term are showing as below:
HAM:HTD'
s EV-to-FCF Range Over the Past 10 Years
Min: 6.67 Med: 19.29 Max: 123.97
Current: 110.3
During the past 13 years, the highest EV-to-FCF of Corcept Therapeutics was 123.97. The lowest was 6.67. And the median was 19.29.
HAM:HTD's EV-to-FCF is ranked worse than 89.16% of 332
companies
in the Biotechnology industry
Industry Median: 17.465
vs HAM:HTD: 110.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Corcept Therapeutics's PE Ratio (TTM) for today is calculated as:
Corcept Therapeutics's share price for today is €97.56.
Corcept Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Corcept Therapeutics EV-to-FCF Related Terms
Corcept Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corcept Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's EV-to-FCF falls into.
Corcept Therapeutics's current Enterprise Value is €10,214.1 Mil.
Corcept Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €91.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (HAM:HTD) has a EV-to-FCF of 111.69 as of Aug. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Corcept Therapeutics and its competitors. This is 479% above median its historical median of 19.29. Over the past decade, Corcept Therapeutics' EV-to-FCF has ranged from 6.67 to 123.97. According to the industry distribution chart, Corcept Therapeutics ranks #296 out of 332 companies in the Biotechnology industry, placing it in the top 89.2%.
Is Corcept Therapeutics' EV-to-FCF too high?
Corcept Therapeutics' current EV-to-FCF of 111.69 is 479% above median its 10-year median of 19.29. Over the past 10 years, this metric has ranged from a low of 6.67 to a high of 123.97. The Biotechnology industry median EV-to-FCF is 17.47. Corcept Therapeutics' value of 111.69 is 539.5% above this industry median. Based on the distribution chart, Corcept Therapeutics ranks #296 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' EV-to-FCF compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #296 out of 332 companies for EV-to-FCF. This places Corcept Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 17.47. Corcept Therapeutics' value of 111.69 is 539.5% above this benchmark. Historically, Corcept Therapeutics' own EV-to-FCF has ranged from 6.67 to 123.97 over the past decade. While the company's 10-year median is 19.29 vs. the industry median of 17.47, Corcept Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.47, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current EV-to-FCF of 111.69 is 539.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current EV-to-FCF is 111.69, which is 479% above median its own 10-year median of 19.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (HAM:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €59.87, compared to a current price of €97.56 — trading 63% above its estimated fair value. The current EV-to-FCF is 111.69, which is 479% above median its 10-year median of 19.29 and 539.5% above the Biotechnology industry median of 17.47. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current EV-to-FCF is 111.69 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €97.56 is trading 63% above its estimated GF Value™ of €59.87.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for HAM:HTD:
EV-to-FCF: 111.69 (479% above median its 10-year median of 19.29)
GF Value™: €59.87 vs. price of €97.56 (63% above fair value)
Industry Position: 539.5% above the Biotechnology median (#296 of 332)
No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for HAM:HTD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:HTD has been successfully added to your 
